Hemophagocytic lymphohistiocytosis following reactivation of Epstein–Barr virus infection – A rare case report | Zendy

Chandrasekar Sundaram | Zendy; R. T. Shriramganesh | Zendy; Sangeetha Geminiganesan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hemophagocytic lymphohistiocytosis following reactivation of Epstein–Barr virus infection – A rare case report

Author(s) -

Chandrasekar Sundaram,

R. T. Shriramganesh,

Sangeetha Geminiganesan

Publication year - 2020

Publication title -

indian journal of medical sciences

Language(s) - English

Resource type - Journals

eISSN - 1998-3654

pISSN - 0019-5359

DOI - 10.25259/ijms_194_2020

Subject(s) - hemophagocytic lymphohistiocytosis , medicine , fulminant , asymptomatic , immunology , epstein–barr virus , jaundice , hemophagocytosis , population , epstein–barr virus infection , fulminant hepatic failure , virus , virology , pancytopenia , pathology , gastroenterology , liver transplantation , bone marrow , transplantation , disease , environmental health

Hemophagocytic lymphohistiocytosis (HLH) is a catastrophic condition, leading to the rapid incitement of immune-mediated cells. Asymptomatic primary Epstein–Barr virus (EBV) infection is common in the general population, while EBV causing acute hepatitis and jaundice is uncommon and acute liver failure has been rarely reported. Here, we report a case of fulminant hepatic failure and HLH following the reactivation of EBV infection that was successfully treated with dexamethasone therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research